One of these compounds is selumetinib (75 mg, twice daily, orally), which was reported to be efficacious in treating KRAS mutation-positive advanced NSCLC when paired with docetaxel but failed to promote survival in lung cancer patients in phase III trials [119,156]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.